The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy.
 
Jason Alan Chesney
Consulting or Advisory Role - Amgen; Replimune
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; MedImmune; MedImmune; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents
Travel, Accommodations, Expenses - Amgen; Replimune
 
Mohammed M. Milhem
Honoraria - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Priya Gokani
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Wendy Snyder
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Caroline Robert
Consulting or Advisory Role - Amgen; Biothera; Bristol-Myers Squibb; CureVac; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi